Dyve’s TARGETS Phase 2 Study Abstract Presented at ACR

When: November 14, 2022
Where: Philadelphia, PA
Topic: “The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study”. 

Presented by Dr. Puja Khanna, the study provides evidence of systemic pH modulation demonstrated as part of our TARGETS Phase 2 study of DYV700. 

Scroll to Top